CINECA IRIS Institutional Research Information System

BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 428
EU - Europa 21
NA - Nord America 7
Totale 456
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 404
SG - Singapore 24
IT - Italia 20
MX - Messico 6
DE - Germania 1
US - Stati Uniti d'America 1
Totale 456
Salva come PNG Salva come JPEG
Città #
Hong Kong 404
Sona 20
Singapore 18
Mexico City 6
Düsseldorf 1
Totale 449
Salva come PNG Salva come JPEG
Nome #
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 14
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +  13
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 13
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 13
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 12
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 12
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 12
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 12
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 12
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 12
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 12
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 12
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 11
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 11
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 11
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 11
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 11
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 11
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 11
AISF position paper on HCV in immunocompromised patients 11
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 11
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 9
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 9
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 8
Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with Peg-Interferon and Ribavirin 7
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 7
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 6
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 6
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 6
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 5
Recent breakthroughs in the treatment of chronic hepatitis Delta 5
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 5
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 5
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 5
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 4
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 4
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 4
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 4
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 4
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 4
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 4
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 4
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 4
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues 4
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 4
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 4
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 4
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 4
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 4
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 4
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 4
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 4
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 4
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 4
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 4
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 4
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al 4
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 4
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study 4
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 4
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 4
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 4
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 4
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 4
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 4
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 3
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 3
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 3
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 3
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 3
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 3
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 3
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 3
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 3
Virological patterns of HCV patients with failure to interferon-free regimens 3
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 3
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 3
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 3
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 3
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 3
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 3
Hepatitis delta infection in Italian patients: towards the end of the story? 3
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 3
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 3
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 3
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 3
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 3
Hepatitis C Virus Clearance in Older Adults 3
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 3
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 3
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 3
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 3
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 3
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 3
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 3
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 3
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 3
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 2
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 2
Totale 555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025555 0 0 0 0 0 0 0 0 139 416 0 0
Totale 555